#12Q22 Presentation September 2022 eurofarma Eurofarma#22 DISCLAIMER This presentation may contain information about future events, such information would not only be historical facts, but would reflect the wishes and expectations of the company's management. The words "believes", "expects", "plans", "forecasts", "estimates", "projects", "aims" and the like are intended to identify statements that necessarily involve known and unknown risks. Known risks include uncertainties, which are not limited to the impact of price and service competitiveness, acceptance of services in the market, service transactions by the company and its competitors, regulatory approval, currency fluctuation, changes in the mix of services offered and other risks described in the Company's reports. This presentation includes accounting and non- accounting data. Non-accounting data has not been subject to review by the Company's independent auditors. Certain percentages and other amounts included in this document have been rounded up to facilitate their presentation. The scales of the charts can appear in different proportions, to optimize the demonstration. Accordingly, the numbers and charts presented may not represent the arithmetic sum and the appropriate scale of the numbers that precede them and may differ from those presented in the financial statements. This presentation does not constitute or should be considered an offer or solicitation to buy or sell any financial instrument or to participate in any specific business strategy. This presentation was updated as of June 30, 2022, and the Company does not assume any obligation to update it in light of new information or future developments. eurofarma#33 01 Overview 02 Eurofarma 03 Results 04 Team and ESG Agenda 05 Annexes eurofarma#44 50 YEARS OF HISTORY to Become a Leading Pharmaceutical Company 1972 founded Billi Pharmaceutical Foundation 1977 First mover in outsourcing for other pharma (Carlo Erba Lab) 2001 Entrance into generic market 2002 Beginning of exports 1979 Acquisition of the 1st production unit in Brazil 1982 Acquisition of the 1st 1987 Acquisition of Majer Meyer's Brazilian laboratory to produce penicillin brands 1992 Acquisition of Stanley Home do Brasil Brazil Expansion: 1993 Eurofarma brand created 1997 Acquisition of Pearson 1995 Startup of facilities of Freguesia do Ó and Euroglass 1998 Wyeth's brand acquisition 2006 Foundation of Innovation Business Unit, Instituto Eurofarma and Magabi 2007 Inauguration of the Itapevi complex eurofarma 2011 Supera Farma JV created with Cristália 2014 Stake acquired in Melinta Therapeutics and partnerships with Dong-A 2012 Start of Colombia operation and Orygen Biotech (partnership with Biolab) 2015 Registration of the 1st biosimilar medicine in LatAm 2019 #1 Prescription in Brazil Neuron Ventures Acquisition of Medipharm in Chile and Buxton in Argentina Lactare, the first private milk bank owned by a pharma company in Brazil Next Stage of Growth 2020 Eurolab oppening Acquisition of Takeda and Lilly's portfolio in the 2nd largest pharma market in Latam (Mexico) 2009 Acquisition of Quesada and Eurofarma Argentina foundation; International Expansion 2010 Acquisition of Gautier (Uruguay and Bolivia), Volta and Farmindustria (Chile) and Segmenta (Brazil) 2017 Unprecedented method of home decontamination of primary packaging approved by Anvisa 2018 Acquisition of Stein's portfolio in Central America 2021 Partnership with Pfizer and Biontech for the Covid-19 vaccine in Brazil Registration of the first international patent for an innovative molecule Portfolio acquisition from Hypera in Colombia and Mexico 2022 50 years anniversary nossa historia tem tem a sua marca Grupo Eurofarma 50 anos#55 EUROFARMA AT GLANCE One of the Leading LatAm Pharma Company 50 Years of history ++ 1 Products in the pharma' ~8,000 employees #1 prescription #3 pharma main segments in Brazil and abroad pharma in Brazil¹ in Brazil² LEADERSHIP Eurofarma COMPETITIVENESS sales force +3,000 salespeople 27.3% 2021 Adjusted EBITDA margin R$1.9 bi # 2021 Adjusted EBITDA4 26% CAGR 2017-2021 www EXPANSION 20 countries presence 100% LatAm coverage eurofarma #2 pharma in LatAm³ INNOVATION +300 projects on pipeline R$363 mm R&D Expenses in 2021 RECOGNITION 18 years Great Place to Work 4x Sustainability Ranking5 (the only pharma company) (1) Eurofarma, Momenta and Supera; Close-up Jun/2022; (2) IQVIA: Retail Reais PPP/NRA Reais PP (Total Pharmaceutical Market, excluding Covid-19 vaccines) Jun/22; (3) Excluding multinational pharma companies not based in LatAm; (4) Adjusted for R&D expenses; (5) Guia Exame Award.#66 eurofarma COMPLETE PORTFOLIO Growth Profile Institutional 1H22 Consolidated Net Sales1 R$3.9 bi (+12.5% vs. 1H21) Prescription 63,4% Generic 16,4% Hospitals 7,7% Oncologic 2,3% Public Sector 5,1% Others2 23 5,1% Prescription #1 9.6% market share (Close-up) #2 6.2% market share Generic (IQVIA) market share #2 14.2% (IQVIA) Hospitals #7 3.8% market share #1 Oncologic (IQVIA) #11 1.6% market share #32 (IQVIA) Public Sector (Bids) market share #19 1.5% (QVIA) Latin America #3 3.4% market share (IQVIA) Regional-based pharma4 (IQVIA) #2 Brazil 5 #3 5.9% market share (IQVIA) 1- Eurofarma Corp (Eurofarma+Momenta+Supera) / 2- OTC + Outsourcing Services + Exports / 3- Excluding multinational pharma companies not based in Brazil / 4- Excluding multinational pharma companies not based in Latin America / 5- Retail Reais PPP / NRA Reais PP (Total Pharmaceutical Market, excluding Covid-19 vaccines).#77 eurofarma LEADERSHIP POSITION IN THE MAIN THERAPEUTIC CLASSES Positioned to Further Grow Market Share by ATC Level I Dec/21 Market Size (R$ bn) 18.3 7.0 12.6 3.0 7,7 6,1 22,4 11,6 8,5 8,7 21,7 Sales by Therapeutic Class 13 (%) Growth x Market (1) +4.4% +2.8% +5.0% +7.0% +8.6% +6.6% +8.5% +7.2% (1.8%) (6.2%) (12.2%) R$ 129,8 bn Market Position #2 #2 #3 #4 #5 #5 #6 #6 #9 #10 9.3% 12.9% Nervous System Genitourinary System 8.2% XXX Anti-infective System 9.3% Hormonal System 7.4% 6.6% 4% 5% 3% 23% 9% 13% 5.8% 4.2% 4.1% 6% 3.4% 14% 7% 1.9% 4% + MuscleBones System Blood System Digestive System Cardiovascular & Metabolism System Respiratory System Dermatological Others² 1- Eurofarma compounding annual growth rate from Sep/2017 to 2021 compared to sector compounding annual growth rate; 2- Others (antineoplastic and immunomodulatory agents + hospital solutions + antiparasitic, insecticide and repellent products + miscellaneous); 3- Considering ATC III classes in which the Company is present as a % of the total addressable market. 12%#88 eurofarma LEADERSHIP POSITION IN THE MAIN THERAPEUTIC CLASSES Diversified Portfolio Market Share by ATC Level I Dec/21 % of sales 3,5% 2,8% 2,4% 2,1% 2,0% 1,9% 1,9% 1,8% 1,8% 1,8% 1,7% 1,7% 1,7% 1,6% 1,5% 1,5% Market position #2 #1 #1 #1 #1 #1 #1 #1 #1 #1 #2 #1 #4 #1 #3 #2 #1 #1 28.0% 44.6% 36.8% 33.8% 59.1% 45.9% 45.8% 32.4% 20.6% 25.0% 21.5% 9.4% 52.2% 29.2% 24.1% 16.1% 1,4% 1,4% 1,3% 1,2% #1 #1 #2 #2 84.7% 56.7% 27.9% 20.8% #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 #14 #15 #16 #17 #18 #19 #20 R$2.8 bn #2 37.2% Top 20 products as % of total revenue Source: Retail and non-retail sales channels in R$ PPP, Dec21 | Eurofarma, Momenta and Supera; Total combined revenue of top 20 products Ranking among top 20 best anti-infective market products TOP 20 products: #1 Enoxaparin Sodium, #2 Piperacillin/ Tazobactam, #3 Ethinylestradiol/ Gestodene, #4 Quetiapine, #5 Paroxetine, #6 Cyproterone/ Ethinylestradiol, #7 Pantoprazole, #8 Tadalafil, #9 Betamethasone, #10 Amoxicillin/ Clavulanic Acid, #11 Azithromycin, #12 Colecalciferol, #13 Hydrochlorothiazide/ Olmesartan Medoxomil, #14 Escitalopram, #15 Desvenlafaxine, #16 Sertraline, #17 Lithium, #18 Levofloxacin, #19 Ceftriaxone, #20 Heparin. *Only retail channel (pharmacy)#99 SALES STRATEGY Pharmaceutical Retail Supported by Solid Grounds ६ Unparallel Nationwide Distribution Capillarity Massive retail capillarity • 91% of cities (Brazil) • 99% of pharmacies Strong and Highly Skilled Sales Platform Largest sales force in • pharma retail • +3,000 salespeople with high engagement • • eurofarma Complete Portfolio Presence in all therapeutic classes Powerful R&D with a constant level of new launches #1 Prescription Top Sales 9.2% Market Share Largest Coverage +80% Medical Prescribers Culturally Oriented Strong Marketing Strategies + Brand Awareness Sales DNA at the core of Eurofarma's strategy Same level of engagement among all kind of physicians Drugstores (POS Points of Sale) End Customers#1010 10 INTERNATIONALIZATION STRATEGY Continuous M&As in LatAm eurofarma Beginning of the LatAm expansion Acquisitions of 2 leading regional pharmas 52% LatAm coverage Further expansion to new markets and consolidation process 64% LatAm coverage Expansion to Central America 100% LatAm coverage Entrance in the 2nd lagest market 100% LatAm coverage 2009 Q QUESADA FARMACEUTICA Acquisition of regional pharma 2010 2012-2013 Facility from MERCK INVENTING FOR LIFE GAUTIER Farmaindustria and A Volta Laboratorios 25th largest local pharma REFASA 2019 2020-2021 SSTEIN CORP. Prescription drug line with +90 products medipharm LABORATORIO From 45th to 21st in Chilean market Successful acquisitions in Mexico Takeda 12 licensed brands US$161mm acquisition Lilly #1 prescribed antibiotic US$30mm acquisition Product acquisition from Craveri Lab BUXTON Focus on biological products Product acquisition from Bayer Lab#1111 GEOGRAPHIC CAPILLARITY Increase in Results #22 #34 1.2% #105 0.6% 0.1% 2016 2021 2026e Colombia 12.3% International Operations Net Revenue (R$ million) Ecuador 2.2% EBITDA and Margin² (R$ million) #30 #14 1.7% #12 2.8% Peru 1.0% 16% 16% 9.6% L 2016 2021 2026e 15% #28 #18 4% #12 2.4% Bolivia 0.8% 1.0% +21% 2016 2021 2026e 1.9% Paraguay +394% 634 523 1H21 1H22 % Consolidated Net Revenue 0.5% Pharma Total Market¹ Chile 101 US$ bi (Retail + Non-retail) 13.6% #11 #18 20 1H21 44% 56% 54.3 2.2% 1.6% 1H22 #62 0.3% EBITDA Margin Brazil LatAm (ex-Brazil) 2016 2021 2026e 1- IQVIA, excluding Covid-19 vaccines / 2- Adjusted and management data #30 #38 0.8% 1.3% eurofarma 2026e Mexico 22.7% 2021 Central America and Caribbean #10 23.5% #40 0.6% #17 1.4% 2.3% 2016 2021 2026e Market Share and Ranking #7 #10 2.9% #12 2.6% 3.8% Uruguay 5.9% % % International sales operations (1H22) ✓ Production Facilities Argentina 7.8% 2016 2021 2026e#1212 12 GEOGRAPHIC CAPILLARITY Increase in Results Brazil Operations Net Revenue (R$ million) 85% 84% +11% EBITDA and Margin² (R$ million) 29% 27% +21% Pharma Total Market¹ US$ bi (Retail + Non-retail) 44% 56% 54.3 3,218 Brazil LatAm (ex-Brazil) 2,901 941 779 1H21 1H22 % Consolidated Net Revenue 1- IQVIA, excluding Covid-19 vaccines / 2- Adjusted and management data 1H21 EBITDA Margin 1H22 %% consoldated net revenue (1H22) Production Facilities eurofarma Brazil 84%#1313 33 Incremental Innovation Investments in R&D Well-Defined Innovation Journey R&D Investments (R$ million) 1 Similars and Generics eurofarma 363 CAGR 23% 271 +35% 248 210 2 3 Radical Innovation - Partnerships 198 158 AS 4 Own Radical Innovation 156 2017 2018 2019 2020 2021 1H21 1H22 % Net 5.1% 5.3% 5.6% 4.3% 5.1% 4.6% 5.5% Revenue#1414 LAUNCHES IN ALL SEGMENTS Well-Defined Innovation Journey International ciprofloxacino Eurofar Eurofarma Hormus Matiz testosterona undecilato de 250 mg/mL USO AQUALID Eurofarma ABIRATERONA/Rustatina ACETATO DE ABIRATER Rosuvastatina 250 mg Eurofarm Ainda SR Indapamida 10 mg Eurofarma 1.5 mg Conten 1 ampolla con 4 Choriomon® Gonadotropina Coriónica Humana 5000 UI Eurofarma Ribex 20 Ribex 20 Rivaroxabán 20 mg Ribex 15 Rivaroxabán 15 mg Suganon Evogliptina 5 mg Eurofarma Gésico Dun Tramadol - Parar 37,5 mg-32 Rivaroxabán Eurofarma Ribex 15 Rivaroxaban Euroterma Ribex 10 Rivaroxabán 10 mg Eurofarma Ribex10 Rivaroxabán 10 mg Eurofarma Clavam Duo® Accu-Acto C 075 mg +125 mg Eurofarma Tamiram Jelloxacion Eurofarma Tamiram levofloxacino hemi-hidratado 500 mg Eurofarma Pantocal 40 Partopraz Tamiram levofloxacino Eurofarma Eurofarma Bicerto Ketoprofeno 150 mg Eurofarma Tamiram levofloxacino hemi-hidrataco Tamiram levofloxacino hemi-hidratado Tamiram hemi-hidratado 750 mg Eurofarma arma 40 Desve 100 100 mg INTERCAMBIABLE Launches and New Products (#Brazil and LatAm) eurofarma +340 +40 Carte 5 Comps roberte 138 +300 ciprofloxacino 400 mg/2 mg 10,2 ciprofloxacino 110 86 tursterna Esc ODT oxalato de escitalopram 98 55 92 87 93 65 55 28 37 49 Eurofarma carbonato de litio 300 mg 49 36 83 Ma Gend 49 55 Isotretinoina 29 38 55 65 20 mg 2017 2018 2019 2020 2021 1H22 2022e nerico UmBi Gotas Brazil Bir Carbol carbonato 300 mg Eurofarma Eurofarma carbona Carbolitium Carbo Carbolitium Carbolitium CR ESC ODT Esc OD Esc ODT carbonato de litio 450 mg 300 mg carbonato de 450 mg Oxalato de escitac Oxalato de escha axaleto de escit carbonat 10 mg 450 m bilastina Eurofarma bilastina furoato de mometasona furoato de mometas Neo B Vent furoato 10mometa Artico Saché Ventus furoato de 20 mg Eurofarma 20 mg 50 m Nai bilasti Naire bilastina 20 mg 20 ma E fusterna Citobê nitrato de tiamine cloridrat idrato de pirid cianocobalamina Momenta His bilast 20 m Moments Hisbila bilastina 20 mg Monax furoato de mometasona Artico Sache 13-12 drospin estradi drospirenon etinilestradi Delabaxi delafloxacino meglumina 300 mg Artico Sache de pess drospirenona 3 etinilestradiol 0,02 Eurofarma Vitamina IDexalgen NF Rebrive sugamadex sódico 100 mg/mL Eurofarma Momenta Eurofarma Alurax dienogeste mg 90 comprimidos revestidos ImBiGotal INSOLUCIO DOTAS 88-12 8 mL Momenta#1515 15 HIGHEST MARKET SHARE IN NEW RELEASES Unique Pipeline for the Near Future Market Share of Released Products Launches by Brazilian pharma in the last 24 months Eurofarma's Portfolio Renewal Index Released products in the past 24 months as a % of total portfolio eurofarma eurofarma 8.8% 13.7% GRUPO NC Hypera pharma achē 6.7% 11.6% 11.5% 9.9% 10.0% 10.2% 10.5% 10.1% 5.5% 8.9% 4.6% -30% of revenue 8.4% 2.3% APSEN FARMACEUTICA biolab from launches of last 5 years 2.2% -15% of revenue FQM 1.9% 1.5% from launches of last 3 years 2014 2015 2016 2017 2018 2019 2020 2021 1Q22 2Q22 Libbs Highest Efficiency in the Development and Release # of released products between 2017-2021 Current Innovation Pipeline # and R$ million 2,781 3,664 4,545 5,343 164 322 868 1,093 689 133 65 117 441 4 361 371 346 48 43 269 63 258 3 3 47 43 40 05 224 199 35 34 50 25 50 19 18 149 42 38 0 15 0 9 15 eurofarma achē GRUPO NC biolab CRISTALIA Hypera NOVARTIS Libbs SANOFI→ 11 5- -3 15 1-0 7 3 8 TEUTO Average days to release # of released products 2022 2023 2024 Licenses Prototype list 2025 Development list 2026 2027 2028 Expected Revenue#1616 1 NEURON -VENTURES- R$45mm AuM Founded in 2019 Worldwide investments, focused in early-stage startups with potential synergies with Eurofarma's businesses companies In the portfolio Target sectors include • • Industries & Logistics, Healthcare and • Diagnostics healthcare boll Hundreds of chromatography and 12 synthesis chapels 6 laboratories state-of-the-art Invested Portfolio T the men's OCEAN DROP rockcontent PSICOLOGIAVIVA Jusor You Oli Nexfar by PSYALIVE Staggering factory (minifactory will be able to produce batches for clinical studies) eurofarma INNOVATION Going Beyond with Constant New Initiatives Rooms EUROLAB dedicated to the development of formulation and analytical Innovation Hub methodologies Other Initiatives Synapsis Eurofarma. EMERGE Program to support entrepreneurs with high growth potential Average growth of 59% in topline of participant companies 80% of participants made a pilot project with Eurofarma Project focused on further developing innovation by funding scientists to take their academic research to market Access to knowledge in biotech through limited partnership since 2020 with venture capital fund (Abingworth) +670 molecules already designed and obtained for the design of new drugs Largest organic synthesis laboratory in LatAm dedicated to small organic molecules AS#1717 FINANCIAL HIGHLIGHTS Historical Net Revenue (R$ million) CAGR 23% 5,723 4,828 3,702 3,122 7,068 Adjusted EBITDA1 (R$ million) Net Income (R$ million) Net Debt/ EBITDA (x) 1,929 1,000 CAGR 26% +13% CAGR 28% 849 1,529 +28% +11% 3,852 1,178 1,178 3,423 912 923 761 580 491 483 434 368 0.35 eurofarma 0.67 0.47 1.00 0.87 0.90 0.05 2017 2018 2019 2020 2021 1H21 1H22 2017 2018 2019 2020 2021 1H21 1H22 2017 2018 2019 2020 2021 1H21 1H22 2017 2018 2019 2020 2021 1Q22 2Q22 Margin 24.4% 24.6% 24.4% 26.7% 27.3% 27.0% 30.6% 11.8% 13.3% 12.0% 14.8% 14.1% 12.7% 12.5% 1- Adjusted for R&D expenses#1818 COMPANY'S MANAGEMENT Expertise with Extensive Knowledge of the Pharma Industry .......... Maurizio Billi CEO Eurofarma eurofarma Alexandre Palhares Finance VP Julio Cesar Gagliardi Commercial VP Marco Billi International and Entrepreneurship & Digital VP Maria del Pilar Muñoz New businesses & Sustainability VP Martha Penna Innovation VP Mikiko Shoji HR VP Roberta Resende Operations VP Douglas Garcia International (South) Emilio Neto International Executive Director Executive Director (North) marketing Executive Paula Mamberti International Director Romulo Garcia International (South) Rosalba Pantoja Executive Director Walker Lahmann Institutional relations Executive Director International operations Executive Director#1919 19 ESG Principles and Practices that Permeate and Guide Eurofarma Since its Creation Environmental Social eurofarma Governance 1st Brazilian pharma with a commitment to neutralize 100% of direct CO2 emissions Energy Efficiency ☐ 1st Brazilian pharma with ISO 50001:2018 certification Energy matrix with 29% renewable sources Water Efficiency Increased reuse in utility processes Reduction of 4% in total water consumption, weighted by the volume produced, totaling 434,518 m³ Circular Economy +VERDE Decontamination of primary packaging by consumers and with homemade solutions ■ 100% of medication packaging contains guidelines on correct disposal 30% recycled material in secondary packaging 12.3 million units sold in 2021 Eurofarma Institute Since its foundation, R$125 million have been invested and more than 115,000 services have been provided. ■ In 2021, was invested R$14.3 million in the Institute with around 10 thousand direct beneficiaries Humanitarian Aid Expansion of hospital, hiring of health professionals, donation of medicines and food baskets Since the beginning of the Covid-19 pandemic, more than R$70 million has been allocated, of which R$39.5 million in 2021 Grupo Eurofarma +DIVERSO ++ Program that works on 4 priority fronts (Gender, Race, People with Disabilities and LGBTQIA+), has the direct participation of 150 employees in affinity groups In 2021, Eurofarma held its 1st Diversity Week ◉ Corporate Integrity Compliance, risk management, internal audit, privacy and protection of personal data and complaints channel Code of Ethics Suppliers code Qualified and experienced Board of Directors formed by mostly of independent members ☐ BoD Members: " ◉ Maurizio Billi (Chairman) Claudio Roberto Ely* Cristina Palmaka Eduardo Job* ☐ Juliana Rozenbaum* Marcelo Martins* ◉ Marco Billi Maira Billi Nelson Mussolini* *independent member#203 eurofarma your life moves ours Investor Relations ri.eurofarma.com.br [email protected]#21Annexes 150ml eurofarma#22GRUPO NC Hypera eurofarma SANOFI NOVARTIS 6,5% 22 22 OUTSTANDING POSITION Solid and Consistent Growth 1Q22 Pharmaceutical Market Share Brazil¹ #3 6,0% 5,9% 4,8% 4,2% 4,2% 3,7% 3,4% achē gsk Johnson Johnson novo nordisk Takeda (૫008 2,5% 2,2% 2,2% 2,1% 2,1% 2,0% 1,9% MSD União Química AstraZeneca CAGR Net Revenue 2019-20213 21% 18% Brazil Total 45% International Source: IQVIA: Retail Reais PPP/NRA Reais PP (Total Pharmaceutical Market, excluding Covid-19 vaccines) Mar/22 | 1- Eurofarma, Momenta and Supera; 2- Excluding multinational pharma companies not based in Latin America and Bolivia - MAT Feb/22; 3- Net revenue: R$4,828 mm (2019), R$5,723 mm (2020) and R$7,068 mm (2021). CIMED ROEMMERS eurofarma Hypera 4.0% #2 3.4% 3.2% LatAm² eurofarma#2323 23 Key Consolidated Financial Indicators 1H22 Results (R$ million)1 Net Revenue 1- Variation compared to 1H21 2- Adjusted for R&D expenses R&D R$ 3,852 Adjusted EBITDA² Gross Profit Operating Expenses eurofarma +13% R$ 2,567 +14% R$ 1,591 +5% Gross Margin -1.0 p.p. 66% % Net Revenue 41% -2.8 p.p. Net Income $ R$ 210 % Net Revenue 5.5% +35% +0.9 p.p. R$ 1,178 Adjusted EBITDA Margin 31% +28% +3.6 p.p. R$ 483 Net Margin 13% +11% -0.1 p.p. Operating Cash Flow R$ 1,166 +199#2424 EXPANSION INVESTMENTS New Plant in Montes Claros (MG) eurofarma The Plant ☑ Expanding to Minas Gerais - Brazil Estimated startup In 2023 Total area +538,000 sqm Total estimated investment R$1.3 billion With R$748 million invested Highlights +120 million units/shift per year and 770 SKUs estimated to be produced Tax benefit due to SUDENE and over ICMS (MG) Expectation to be certified by worldwide healthcare agencies, including USA Mexico • Argentina • Brazil • Peru • ⚫ Colombia#2525 25 FOOTPRINT Presence Throughout LatAm Plants Total area Inauguration year Installed Capacity (mm) Peru 2.1k m² 2013 11.8 un 1- Inauguration year of first plant of Itapevi complex; 2- Year of acquisition 3- Under construction Colombia 16.9k m² 2012 22.6 un Chile Cerrillos and Pudahuel 23.8k m² 2019 and 2014² 33.8 un Guatemala 32.6k m² 2013 6.7 un & eurofarma Brazil Itapevi, Ribeirão Preto, Freguesia do Ó and Montes Claros³ +870k m² 20071/20102/20132 +770 un Argentina 33.9k m² 2015 23.9 un Uruguay 2.7k m² 2010 5.7 un#2626 Latin America Pharma Total Market (Retail + Non-Retail) Market- MAT Total US$54.3 bn Venezuela Peru Uruguay Ecuardor 3% Chile 3% 1% Central America + 4% 1% Dominican Republic 6% Colombia 9% 10% Argentina 20% Mexico Brazil 44% 1- Source: IQVIA Mar/2022 | Retail PPP / Non Retail - Reais PP, excluding Covid-19 vaccines (R$163.4 bi considering vaccines). eurofarma ■ Latin America According to IQVIA, the Latin America market (retail + non-retail) is expected to grow 11-14% per year between 2022 and 2025 Population aging and lifestyle habits drive demand for medicines According to a study from the Latin American Development Bank, nowadays 8% of the population is 65 years old or over (below the European average, at 17.5%). ■ It is estimated that the LatAm population over 65 years old will reach 30% by 2050 ■ Economic recovery post-Covid ■ Increased access in retail through greater adoption of generics and in non-retail through biosimilar adoption#2727 22 Brazilian Pharma Total Market (Retail + Non-Retail) Market- MAT (R$ billion) +11,5% +29,0% 119 CAGR +16% +10,6% +12,6% 149 132 58 107 52 52 46 83 41 26 57 40 91 73 80 67 2017 2018 2019 Non Retail Retail 2020 2021 1- Source: IBGE and IQVIA Mar/2022 | Retail - Reais PPP / Non Retail - Reais PP, excluding Covid-19 vaccines (R$163.4 bi considering vaccines). eurofarma ☐ Brazil According to IQVIA, the Brazilian market (retail + non-retail) is expected to grow 9-12% per year between 2022 and 2026 Population aging and lifestyle habits drive demand for medicines According to IBGE, ~10.7% of the Brazilian population was 60 years old or older in 2010. It increased to 14.3% in 2020 and it is estimated that, the population over 60 years old will represent 32.2% in 2060 ■ Gradual recovery in income levels due to slow economic recovery Adoption of new technologies in smaller portions of the population#2828 eurofarma World Pharma Market Forecast Change in Prognosis The LATAM region is forecast to show the strongest growth at a CAGR of 12.6% between 2020 and 2025, while Japan is forecast to decline at a CAGR of 0.3% 4,8% 4,3% World Total Region 5-year CAGR (LC$) ■2020-2025 Previous Forecast ■2020-2025 Current Forecast 12,6% 10,4% 4,2% 4,1% 4,3% 4,8% 4,5% 3,5% -0,6%-0,3% North America Europe (EU countries) South-East & East Asia Japan 10,9% 9,6% 9,5% 8,6% 6,3% 6,7% 6,2% 5,7% 4,8% 4,9% 2,5% 2,8% Europe (non- EU countries) Indian Sub- Continent CIS Africa Middle East Oceania Latin America, including the Caribbean Current Forecast (Published: Sep 2021) 2021 Annual Growth (LC$) 6.5% 4.8% 6.1% -0.2% 15.9% 7.3% 15.4% 9.5% 3.4% 5.6% 2.5% CAGR 2020-2025 4.2% 4.3% 4.5% -0.3% 12.6% 6.7% 10.9% 8.6% 5.7% 4.9% 2.8% Previous Forecast (Published: May 2021) 2021 Annual Growth (LC$) 5.1% 4.7% 7.0% -0.8% 11.5% 6.8% 10.7% 12.0% 5.0% 4.8% 2.4% CAGR 2020-2025 3.5% 4.1% 4.8% -0.6% 10.4% 6.3% 9.6% 9.5% 6.2% 4.8% 2.5% Source: IQVIA Market Prognosis Global 2021-2025